What is Medable?
Headquartered in Palo Alto, California, Medable operates a sophisticated platform designed to streamline the complexities of clinical trial management. By leveraging patient-generated data, the company enables researchers to conduct more efficient, decentralized, and inclusive studies. Its technology stack is engineered to support precision and predictive medicine, effectively digitizing the clinical research lifecycle. In an era where speed-to-market for new therapeutics is paramount, Medable occupies a vital position, providing the digital architecture necessary for modern, patient-centric clinical trials that meet the rigorous demands of global regulatory bodies.
How much funding has Medable raised?
Medable has raised a total of $518.8M across 6 funding rounds:
Series A
$3.6M
Series B
$16.2M
Debt
$1M
Other Financing Round
$25M
Series C
$169M
Series D
$304M
Series A (2015): $3.6M, investors not publicly disclosed
Series B (2018): $16.2M, investors not publicly disclosed
Debt (2020): $1M supported by PPP
Other Financing Round (2020): $25M featuring PPD, Inc and GSR Ventures
Series C (2021): $169M backed by Streamline Ventures, PPD Group Inc, Sapphire Ventures LLC, GSR Ventures, and The Obvious
Series D (2021): $304M with participation from Tiger Global Management, Sapphire Ventures, GSR Ventures, WTI - Western Telematic, and Blackstone Accelerates Growth
Key Investors in Medable
Tiger Global Management
A prominent investment firm that deploys capital across both public and private markets, known for backing high-growth technology companies.
Sapphire Ventures
A venture capital firm based in Palo Alto that specializes in scaling technology companies through strategic investment and operational support.
GSR Ventures
A venture capital firm focused on early-to-growth stage technology companies, with a strong emphasis on healthcare and digital innovation.
What's next for Medable?
With the recent infusion of capital, Medable is well-positioned to scale its enterprise-level operations and expand its global footprint. The strategic focus will likely center on enhancing its predictive analytics capabilities and deepening its integration with existing clinical research workflows. As the industry shifts toward decentralized trial models, Medable's platform is expected to serve as the foundational layer for future drug development, enabling pharmaceutical sponsors to reduce trial timelines while improving data quality and patient engagement. The company remains a key player to watch as it continues to define the future of digital clinical research.
See full Medable company page
